Freenome raises $254m funding for early cancer detection platform
Betsy Goodfellow | February 16, 2024 | News story | Research and Development | Diagnostics, Freenome, Oncology, cancer detection, funding
Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement of its single-cancer and tailored multi-cancer early detection tests developed on its multiomics platform.
The funding was led by Roche, as well as a16z Life Sciences Growth Fund, the American Cancer Society’s BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, and Squarepoint Capital. Funds and accounts were advised by T Rowe Price Associates, and others.
The company’s initial programmes have focused on colorectal and lung cancer, with a pipeline of single-cancer and multi-cancer tests in development. There are currently two studies underway, PREEMPT CRC which evaluates the company’s blood-based screening test in adults at avarice risk for colorectal cancer, and PROACT LUNG which is intended to validate the company’s lung screening test in current and former smokers over the age of 50 who are eligible for screening via an LDCT scan.
Mike Nolan, chief executive officer at Freenome, commented: “We are grateful for the support and confidence of our investors. Together, we share a commitment to addressing the pressing need for better cancer screening solutions as we drive to make early cancer detection more convenient, accessible and actionable for everyone. With this financing, we are well positioned to realise the full potential of our platform in delivering tests for early cancer detection.”
Betsy Goodfellow
Related Content
InnotiveDx gets £1m grant to advance UTI diagnostics system
InnotiveDx has announced that it has received a £1m grant from Pathways to Antimicrobial Clinical …
University of Birmingham scientists develop new MRI contrast agent
Researchers at the University of Birmingham, UK, have developed a new class of magnetic resonance …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its …
